A forum for healthcare practitioners with an interest in medicinal cannabis

  • Home
  • WELCOME
  • Message for our Members
  • Who we are
  • Join Us
  • Meeting records
  • SCCAC Opinion
  • Contact Us
  • Clinical Papers/Articles
    • Anxiety
    • Chronic pain
    • Chronic Pain - Guidelines
    • Chronic conditions
    • Cannabinoid Hyperemesis
    • Controversies
    • Driving
    • Endometriosis
    • Fibromyalgia
    • General
    • Geriatrics
    • Mental Health
    • Neurology
    • Opioid usage
    • Parkinson's disease
    • Prescribing
    • Real World Evidence
    • Safety
    • Safety
  • Calendar
  • Alerts
  • RIP OLIVIA NEWTON-JOHN
  • More
    • Home
    • WELCOME
    • Message for our Members
    • Who we are
    • Join Us
    • Meeting records
    • SCCAC Opinion
    • Contact Us
    • Clinical Papers/Articles
      • Anxiety
      • Chronic pain
      • Chronic Pain - Guidelines
      • Chronic conditions
      • Cannabinoid Hyperemesis
      • Controversies
      • Driving
      • Endometriosis
      • Fibromyalgia
      • General
      • Geriatrics
      • Mental Health
      • Neurology
      • Opioid usage
      • Parkinson's disease
      • Prescribing
      • Real World Evidence
      • Safety
      • Safety
    • Calendar
    • Alerts
    • RIP OLIVIA NEWTON-JOHN
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • WELCOME
  • Message for our Members
  • Who we are
  • Join Us
  • Meeting records
  • SCCAC Opinion
  • Contact Us
  • Clinical Papers/Articles
    • Anxiety
    • Chronic pain
    • Chronic Pain - Guidelines
    • Chronic conditions
    • Cannabinoid Hyperemesis
    • Controversies
    • Driving
    • Endometriosis
    • Fibromyalgia
    • General
    • Geriatrics
    • Mental Health
    • Neurology
    • Opioid usage
    • Parkinson's disease
    • Prescribing
    • Real World Evidence
    • Safety
    • Safety
  • Calendar
  • Alerts
  • RIP OLIVIA NEWTON-JOHN

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

Endometriosis

Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms

Sinclair J, Collett L, Abbott J, Pate DW, Sarris J, Armour M. Effects of cannabis ingestion on endometriosis-associated pelvic pain and related symptoms. PLoS One. 2021 Oct 26;16(10):e0258940. doi: 10.1371/journal.pone.0258940. PMID: 34699540; PMCID: PMC8547625.


Abstract

Background: The use of cannabis for symptoms of endometriosis was investigated utilising retrospective archival data from Strainprint Technologies Ltd., a Canadian data technology company with a mobile phone application that tracks a range of data including dose, mode of administration, chemovar and their effects on various self-reported outcomes, including pelvic pain.

Methods: A retrospective, electronic record-based cohort study of StrainprintTM users with self-reported endometriosis was conducted. Self-rated cannabis efficacy, defined as a function of initial and final symptom ratings, was investigated across the included symptom clusters of cramps, pelvic pain, gastrointestinal pain, nausea, depression, and low libido. Cannabis dosage form, dose and cannabinoid ratio information was also recorded.

Results: A total number of 252 participants identifying as suffering endometriosis recorded 16193 sessions using cannabis between April 2017 and February 2020. The most common method of ingestion was inhalation (n = 10914, 67.4%), with pain as the most common reported symptom being treated by cannabis (n = 9281, 57.3%). Gastrointestinal symptoms, though a less common reason for cannabis usage (15.2%), had the greatest self-reported improvement after use. Inhaled forms had higher efficacy for pain, while oral forms were superior for mood and gastrointestinal symptoms. Dosage varied across ingestion methods, with a median dose of 9 inhalations (IQR 5 to 11) for inhaled dosage forms and 1 mg/mL (IQR 0.5 to 2) for other ingested dosage forms. The ratio of THC to CBD had a statistically significant, yet clinically small, differential effect on efficacy, depending on method of ingestion.

Conclusions: Cannabis appears to be effective for pelvic pain, gastrointestinal issues and mood, with effectiveness differing based on method of ingestion. The greater propensity for use of an inhaled dosage delivery may be due to the rapid onset of pain-relieving effects versus the slower onset of oral products. Oral forms appeared to be superior compared to inhaled forms in the less commonly reported mood or gastrointestinal categories. Clinical trials investigating the tolerability and effectiveness of cannabis for endometriosis pain and associated symptoms are urgently required.


Copyright © 2022 Society of Cannabis Clinicians Australian Chapter - All Rights Reserved.


Powered by GoDaddy

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept